20
Nov

Go EAST Young Man!

The FDA has published its “Enhanced Approach for Sampling and Testing (EAST) program which proactively monitors the quality of medicines available to American patients and consumers”. The new program utilizes faster, modern testing techniques and traditional methods to efficiently and effectively evaluate more drug products. Under this program, FDA will purchase drug products from retain […]

Read More
18
Nov

How About Those Annual Reports – Don’t Let Them Slide

Ever get behind in submitting your annual report for approved applications? Just too much to do and they slip a bit. The next thing you know you are buried and the annual reports you placed temporarily on the back burner, become the current burning issue. Yesterday in a Federal Register pre-publication notice (here), the FDA […]

Read More
13
Nov
Good Thoughts from an FDA Expert

Good Thoughts from an FDA Expert

Brian Folian, Deputy Office Director, Office of Study Integrity and Surveillance (OSIS), CDER described the functions of his Office during the recent Association of Accessible Medicines GRx + Biosims conference. He noted that his Office is responsible for the oversight of study of the conduct of bioavailability, bioequivalence, pharmacokinetic, pharmacodynamic, good laboratory practice and animal […]

Read More
05
Oct
FDA Looks for Comments on Ibogaine Potential Study Safety Guardrails.

FDA Looks for Comments on Ibogaine Potential Study Safety Guardrails.

The FDA is asking for comments on how the early-phase clinical trials initial study of ibogaine for the treatment of opioid use disorder and post-traumatic stress disorder (PTSD) can be carried out safely. The issue is centered on ibogaine’s association with potentially serious QTc interval prolongation and potential life-threatening Torsades de pointes (TdP) syndrome.  The […]

Read More
09
Sep

Priority Review Voucher Fee for FY 2027 Announced

Today, on the Federal Register’s pre-publication page, the FDA published the new fee that must be submitted for use of a priority review voucher. The notice (here) establishes the “FY 2027 priority review fee rate for use of tropical disease, rare pediatric disease, and material threat MCM priority review vouchers at $1,798,596” (the FY 2026 […]

Read More
03
Sep
looking under a rock

Label Changes Drive Drug Shortage for Estradiol Transdermal Patches

In November 2025 the FDA requested that manufacturers of hormonal treatments for menopausal symptoms make changes to the labeling to remove boxed warnings about a probable risk of breast cancer, cardiovascular disease, and probable dementia because new information evaluated by the Agency has made those warnings obsolete. These changes in labeling have had a dramatic […]

Read More
26
Aug

Etomidate Under Review for Controlled Substance Classification

The Federal Register pre-publication notice published today (here) lists Etomidate as a product with possible abuse potential that will be reviewed for scheduling under the Controlled Substances Act. It is a short-acting anesthetic and mentioned often on TV medical shows when a patient is brought into the ER either unresponsive or in need of immediate […]

Read More
1 2 … 35